Moderna Inc. announced positive interim results from a Phase 1/2 clinical study evaluating its investigational pandemic influenza vaccine, mRNA-1018. The study, involving approximately 300 healthy adults aged 18 and older, assessed the safety and immunogenicity of the vaccine targeting the H5 avian influenza virus subtype. Results indicated a robust immune response, with 97.8% of participants achieving protective antibody levels three weeks after the second dose. The vaccine was generally well-tolerated with no significant safety concerns. Despite positive findings, Moderna was informed that the U.S. Department of Health and Human Services will terminate the award for late-stage development. The company plans to explore alternative paths for advancing the program.